Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Mais filtros

Base de dados
Tipo de documento
Intervalo de ano de publicação
1.
Int J Hyperthermia ; 27(7): 698-707, 2011.
Artigo em Inglês | MEDLINE | ID: mdl-21992562

RESUMO

PURPOSE: We investigated the use of hyperthermia to improve the anti-cancer efficacy of doxorubicin (DOX)-loaded mesoporous silica nanocontainer Si-SS-CD-PEG. The hypothesis was that heat stimulates glutathione-mediated degradation of cyclodextrin gatekeeper, thereby causing the release of DOX from the carrier and DOX-induced cell death. MATERIALS AND METHODS: The release of DOX from DOX-loaded Si-SS-CD-PEG suspended in PBS containing glutathione (GSH) was studied by assessing the changes in DOX fluorescence intensity. The effect of heating at 42°C on the release of DOX from the intracellular carriers was determined with confocal microscopy. The extents of clonogenic and apoptotic cell death caused by DOX-loaded Si-SS-CD-PEG were determined. RESULTS: The release of DOX from DOX-loaded Si-SS-CD-PEG in PBS occurred only when GSH presented in the suspension, and heating at 42°C slightly increased the release of DOX from the carriers. Heating significantly elevated the GSH content in A549 cells and increased the release of DOX from the internalised carriers. Heating the cancer cells treated with the carriers at 42°C markedly increased the clonogenic death and apoptosis. The GSH content in A549 cells was greater than that in L-132 cells, and A549 cells were far more sensitive than L-132 cells to DOX-loaded Si-SS-CD-PEG at both 37°C and 42°C. CONCLUSIONS: Hyperthermia increased the GSH-mediated release of DOX from DOX-loaded Si-SS-CD-PEG. Furthermore, hyperthermia markedly elevated the GSH content in cancer cells, thereby increasing the release of DOX from the internalised carriers and potentiating the DOX-induced clonogenic and apoptotic cell death.


Assuntos
Adenocarcinoma/tratamento farmacológico , Antibióticos Antineoplásicos/administração & dosagem , Doxorrubicina/administração & dosagem , Hipertermia Induzida , Neoplasias Pulmonares/tratamento farmacológico , Nanoestruturas/administração & dosagem , Adenocarcinoma de Pulmão , Linhagem Celular Tumoral , Ciclodextrinas/administração & dosagem , Portadores de Fármacos , Glutationa/metabolismo , Humanos , Polietilenoglicóis/administração & dosagem , Succinimidas/administração & dosagem
2.
Medicine (Baltimore) ; 96(50): e9073, 2017 Dec.
Artigo em Inglês | MEDLINE | ID: mdl-29390303

RESUMO

RATIONALE: Thrombosis due to anastomotic site stenosis is the most common complication in patients with brachio-axillary arteriovenous graft (AVG). Intravascular stent placement may play a special role in the salvage of dialysis grafts that have been previously performed percutaneous angioplasty or surgical procedure on the graft. Herein, we applied a novel stent named Supera which has a high degree of flexibility and resistance to external compression for treating a patient with recurrent venous anastomotic stenosis of brachio-axillary AVG. PATIENTS CONCERNS AND DIAGNOSES: We report a case of the patient with end-stage renal disease who presented with brachio-axillary AVG malfunction. INTERVENTIONS: The patient underwent repeated percutaneous angioplasty with thrombectomy for total graft occlusion, and we placed the Supera stent to salvage the graft. OUTCOMES: Postprocedural Doppler ultrasonography did not show any restenosis on the 1- and 3-month follow-up periods, and average flow volume in the stent was >1000 mL/min. And he has been on dialysis for 6 months without any problems after stent placement. LESSONS: The Supera stent is a useful treatment option of interventional procedure for recurrent venous anastomotic stenosis of brachio-axillary AVG in the clinical practice.


Assuntos
Angioplastia/métodos , Derivação Arteriovenosa Cirúrgica , Oclusão de Enxerto Vascular/cirurgia , Stents , Idoso , Ligas , Veia Axilar , Artéria Braquial , Oclusão de Enxerto Vascular/diagnóstico por imagem , Humanos , Falência Renal Crônica/terapia , Masculino , Diálise Renal , Trombectomia , Ultrassonografia Doppler , Grau de Desobstrução Vascular
3.
Biochem Biophys Res Commun ; 291(4): 1006-13, 2002 Mar 08.
Artigo em Inglês | MEDLINE | ID: mdl-11866466

RESUMO

The antifungal activity and mechanism of HP (2-20), a peptide derived from the N-terminus sequence of Helicobacter pylori Ribosomal Protein L1 were investigated. HP (2--20) displayed a strong antifungal activity against various fungi, and the antifungal activity was inhibited by Ca(2+) and Mg(2+) ions. In order to investigate the antifungal mechanism(s) of HP (2-20), fluorescence activated flow cytometry was performed. As determined by propidium iodide staining, Candida albicans treated with HP (2-20) showed a higher fluorescence intensity than untreated cells and was similar to melittin-treated cells. The effect on fungal cell membranes was examined by investigating the change in membrane dynamics of C. albicans using 1,6-diphenyl-1,3,5-hexatriene as a membrane probe and by testing the membrane disrupting activity using liposome (PC/PS; 3:1, w/w) and by treating protoplasts of C. albicans with the peptide. The action of peptide against fungal cell membrane was further examined by the potassium-release test, and HP (2-20) was able to increase the amount of K(+) released from the cells. The result suggests that HP (2-20) may exert its antifungal activity by disrupting the structure of cell membrane via pore formation or directly interacts with the lipid bilayers in a salt-dependent manner.


Assuntos
Antifúngicos/farmacologia , Proteínas de Bactérias/farmacologia , Candida albicans/efeitos dos fármacos , Fragmentos de Peptídeos/farmacologia , Antifúngicos/antagonistas & inibidores , Proteínas de Bactérias/antagonistas & inibidores , Cálcio/farmacologia , Candida albicans/citologia , Candida albicans/fisiologia , Membrana Celular/efeitos dos fármacos , Parede Celular/fisiologia , Relação Dose-Resposta a Droga , Citometria de Fluxo , Helicobacter pylori , Cinética , Lipossomos/análise , Magnésio/farmacologia , Testes de Sensibilidade Microbiana , Fragmentos de Peptídeos/antagonistas & inibidores , Potássio/metabolismo , Protoplastos/efeitos dos fármacos , Protoplastos/fisiologia , Regeneração , Proteínas Ribossômicas/química
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA